Use of a combination of enoxaparin or unfractionated Heparin and abciximab during percutaneous coronary interventions: A randomized pilot study;Utilización de enoxaparina o heparina no fraccionada en combinación con abciximab durante la intervención coronaria percutánea: Estudio piloto aleatorizado

Revista Espanola de Cardiologia

Volumn 55, Issue 12, 2002, Pages 1261-1266

  Galeote, Guillermo ^a   Hussein, Monser ^a   Sobrino, Nicolás ^a   Calvo, Luis ^a   Sánchez Recalde, Ángel ^a   Sobrino, José A ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Coronary angioplasty; Heparin; Stent

Indexed keywords

ABCIXIMAB; CREATINE KINASE MB; ENOXAPARIN; HEMOGLOBIN; HEPARIN; TROPONIN I; ANTICOAGULANT AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DRUG SAFETY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; COMPARATIVE STUDY; DRUG COMBINATION; FIBRINOLYTIC THERAPY; METHODOLOGY; MIDDLE AGED; SAFETY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PILOT PROJECTS; SAFETY; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0036882366     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-8932(02)76798-5     Document Type: Article

References (23)

1. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
2. Hemker HC. The mode of action of heparin in plasma. University Press, 1987; p. 17-36.
3. Ofosu FA, Barrowcliffe TW. Mechanisms of action of low molecular weight heparins and heparinoids. En: Hirsh J, editor. Antithrombotic therapy, Bailliere's clinical haematology (Vol. 3). London: Bailliere Tindall, 1990, p. 505-29.
4. Weitz JL. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-98.
5. Boneu B, Caranobe C, Cadroy, Dol F, Gabaig AM, Dupouy D, Pharmacokinetic studies of standard UHF, and low molecular weight heparins in the rabbit. Semin Thromb Hemost 1988;14:18-27.
6. Bratt G, Tornebohm E, Lockner D, Bergstrom KA. A human pharmacological study comparing conventional heparin derivative. In vitro and in vivo studies. Throm Haemostas 1985;53:208-11.
7. Zed PJ, Tisdale JE, Borzak S. Low-molecular-weight heparins in the managament of acute coronary syndromes. Arch Intern Med 1999;159:1849-57.
8. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts R, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
9. Theroux P, Waters D, Lam J, Jureau M, McCans J. Reactivation of unstable angina after the discontinution of heparin. N Engl J Med 1992;327:141-5.
10. Gurfinkel EP, Manos EJ, Mejail RI, Cerdá Ma, Duranto EA, García CN, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-8.
11. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
12. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie GG, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the managament of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRISC). Circulation 1997; 96:61-8.
13. The Trombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose ranging trial of en oxaparin for unstable angina: results of TIMI IIA. J Am Coll Cardiol 1997;29:1474-82.
14. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group (ESSENCE) trial. N Engl J Med 1997;337:447-52.
15. Antman EM, and the Trombolysis in Myocardial Infarction (TIMI) Investigators, TIMI IIB. Enoxaparin vesus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double blind, placebo-controlled, parallel group, multicenter trial: rationale, study design, and methods. Am Heart J 1998;135: S353-60.
16. Antman EM, McCabe CH, Gurfinkel EP, Turpie AGG, Bermink PJLM, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina or non-Q-wave myocardial infarction. Results of the Trombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:593-601.
17. Collet JPh, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-63.
18. Karsch KR, Preisack MB, Baildon R, Eschenfelderv V, Foley D, García EJ, et al. Low molecular weight heparin (Reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-bblind, unfractionated heparin and placebo controlled, multicenter trial (REDUCE trial). J Am Coll Cardiol 1996;28:1437-43.
19. Rabah MM, Premmereur J, Graham M, Fareed J, Hoppensteadt DA, Grines LL, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-5.
20. Kereiakes DJ, Fry E, Matthai W, Niederman A, Barr L, Brodie B, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: 'NICE guys finish first'. J Invas Cardiol 2000;12:1-5A.
21. Kereiakes DJ, Fry E, Matthai W, Lengerich R, Howard W, Anderson L, et al. Safety of enoxaparin-abciximab combination for percutaneous coronary intervention: preliminary results of the NICE 4 trial [abstract]. Am J Cardiol 1999;84:67.
22. The Epilog investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1994;336:1689-96.
23. The EPISTENT investigators. Randomised placebo-controlled and balloon angioplasty controlled trial to asses safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.